CD70 and acute myeloid leukemia: Phase 1 and 2 trials are ongoing with cusatuzumab, a first-in-class anti-CD70 monoclonal antibody, in acute myeloid leukemia (AML) in combination with azacitidine and/or venetoclax (NCT04150887).